Skip to main content
. Author manuscript; available in PMC: 2010 Aug 2.
Published in final edited form as: Lancet. 2006 Aug 5;368(9534):489–504. doi: 10.1016/S0140-6736(06)69157-5

Table 3.

Antiretrovirals currently in phase II/III of clinical development

Drug Mechanism Activity against PI and RT resistant strains
Maraviroc MVC CCR5 inhibitor Yes, but not X4 variants
Vicriviroc SCH D Yes, but not X4 variants
Etravirine TMC-125 Non-nucleoside reverse transcriptase inhibitor Yes, also NNRTI-resistant strains
TMC-278 Yes, also NNRTI-resistant strains
n/a MK-0518 Integrase strand transfer inhibitor Yes
n/a GS-9137 Yes